Form 6-K Regencell Bioscience For: May 22

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

Commission File Number: 001-40617

 

Regencell Bioscience Holdings Limited

(Registrant’s Name)

 

9/F Chinachem Leighton Plaza

29 Leighton Road

Causeway Bay, Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

EXHIBIT INDEX

 

Exhibit No.		Description of Exhibit
99.1		Press Release – Regencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 22, 2026

 

	Regencell Bioscience Holdings Limited
	By:	/s/ Yat-Gai Au
	Name:	Yat-Gai Au
	Title:	Chief Executive Officer and
		Chairman of the Board of Directors

 

[Signature Page to Form 6-K]

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE - REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING OF ORDINARY SHARES

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Gadget On Launches TitanSnap: The 100-Tool Magnetic Titanium Card Deck Built for Everyday Carry -- Now Live on Kickstarter
• The National Military Spouse Network Releases White Paper, 'Building Economic Security: Understanding the Military Spouse Employment Lifecycle'
• MISS DIG 811 Celebrates 30 Years of Service for Two Dedicated Team Members